At the beginning of April, Japanese pharmaceutical giant Daiichi Sankyo dumped its multi-billion US dollar investment in India’s Ranbaxy, losing billions of its US $4.7 billion investment in this prominent Indian generics firm, not to mention lost management time. Daiichi made its original investment because it saw the deal as a way to broaden its distribution channels, to gain new products, and to tap into the Indian market. Signs were abundant soon after transaction was announced, however, that the deal might encounter serious problems.
